INTRODUCTION
The immune responses in atopic dermatitis (AD) skin lesions are associated with increased amounts of Th2-type cytokines such as interleukin (IL)-4, IL-10, and IL-13 and relatively low levels of Th1-type cytokines such as interferon-γ (1-3). Various contact sensitizers, such as 2,4-dinitrofluorobenzene (DNFB), 2,4-dinitrochlorobenzene, and the metal allergen nickel sulfate trigger contact hypersensitivity responses in the skin following topical treatment (4) . DNFB treatment preferentially induces atopic dermatitis (AD), a chronic inflammatory skin disease (5, 6) . Thus, DNFB has been applied as a potentially useful hapten to induce contact hypersensitivity responses in NC/Nga mice, a well confirmed AD mice model (7) . Langerhans cells (LCs), members of the family of professional antigen presenting dendritic cells (DCs) in the skin, play an important role in contact hypersensitivity responses (8) (9) (10) . LCs in the skin migrate to regional lymphoid organs to activate naïve T cells as a result of topical application with contact sensitizers. In response to skin sensitization, LCs develop into mature DCs with enhanced expression of major histocompatibility (MHC) class II molecules and several costimulatory molecules. DCs upregulate expression of MHC class II molecules and costimulatory molecules such as CD40, CD54, CD83, and CD86 in vitro in response to contact sensitizers (9, (11) (12) (13) . DNFB mediates production of reactive oxygen species (ROS) and activates p38 mitogen-activated protein kinase (MAPK) and ERK1/2 to regulate CD40 expression (14, 15) . However, exposure of DCs to nickel sulfate stimulates signal transduction pathways and augments expression of MHC class II and several costimulatory molecules in different manners compared to that of DNFB (16) . Macrophages are a subpopulation of cells in the mouse dermis that have gained attention as a useful therapeutic target for contact allergies (17) (18) (19) . In a previous study, we examined macrophage inflammatory protein 2 (MIP-2) expression in topically DNFB-applied skin and the DNFB-treated RAW 264.7 cells (19) . We found that the production of ROS is associated with MIP-2 gene expression induced by DNFB via activation of p38 MAP kinase and ERK1/2 in macrophages (20, 21) . However, the role of macrophages in contact sensitizer-induced hypersensitivity reactions has not yet been clearly elucidated. Here, we show expression of CD80, CD83, and MHC class II molecules in response to DNFB in RAW 264. 7 Fig. 1 ), as reported previously for DCs (9, 11, 13) . DNFB enhanced CD83 surface expression within 3 h, and the expression level subsequently declined over the remaining time points (Fig. 2B and Supplementary Fig. 1 ). In contrast to previously reported results for DCs, DNFB did not increase CD86 expression in RAW 264.7 cells (Fig. 2C and Fig. S1 ), indicating that surface expression of CD80, CD83, and MHC class II molecules but not that of CD86 increased in DNFB-treated RAW 264.7 cells.
RESULTS
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Expression of MHC class II and costimulatory molecules in DNFB-treated primary immune cells
We prepared splenocytes from BALB/c mice to investigate the expression of MHC class II and costimulatory molecules in DNFB-treated primary immune cells. A FACS analysis was performed with fluorescein-conjugated antibodies after the DNFB treatment. The expression of MHC class II molecules and CD80 increased in the B220 + (CD45R + ) cell population from spleno-http://bmbreports.org cytes of BALB/c mice (Fig. 3) , consistent with the results obtained for RAW 264.7 cells ( Fig. 2A and D) . CD86 expression in splenocytes also increased following DNFB treatment; however, the increase was milder than that of the CB80 and MHC class II molecules (Fig. 3) . Interestingly, a new population of cells expressing CD80 and a low level of B220 (CD45R) was observed in DNFB-treated splenocytes (Fig. 3, enlarged image) . Next, we analyzed CD83 expression in the peritoneal cells, splenocytes, and cells of the mesenteric lymph nodes from BALB/c and NC/Nga mice. A CD83 + /B220 + cell population was detected in the splenocytes and cells of the mesenteric lymph nodes from BALB/c and NC/Nga mice (Fig. 4) . In agreement with the results from RAW 264.7 cells, CD83 expression was transiently induced by DNFB treatment and then reduced at 6 h after treatment in the splenocytes and cells of the mesenteric lymph node from BALB/c mice ( Fig. 4A and B) . However, DNFB did not influence CD83 expression in peritoneal CD11b + cells from BALB/c mice (Fig. 4C) . Transient induction and subsequent reduction of CD83 expression by DNFB was also detected in the splenocytes and cells of the mesenteric lymph node from NC/Nga mice ( Fig. 4D and E) . DNFB did not influence CD83 expression in peritoneal CD11b + cells from NC/Nga mice (Fig. 4F) (24) . NC/Nga mice were developed as an AD model animal and originated from Japanese fancy mice at Nagoya University (Japan). Repeated application with DNFB induces AD-like skin lesions in NC/Nga mice (7), and several skin sensitizers provoke hypersensitivity reactions (4) . LCs, the DCs of the skin, play a crucial role in DNFB-induced hypersensitivity reactions (8) (9) (10) . A wide variety of skin sensitizers are capable of stimulating DCs. Exposure of DCs to various skin sensitizers results in the induction of MHC class II and costimulatory molecules such as CD40, CD54, CD83, and CD86 in vitro (9, (11) (12) (13) . However, considering the variation observed during experiments in the THP-1 human monocytic leukemia cell line as a model system, the effect of skin sensitizers on CD83 expression appears to be unstable (25) . We reported previously that DNFB is involved in activating mouse macrophages in the dermis of NC/Nga mice (19) . The results showed that DNFB upregulates MIP-2 expression in the dermis and the RAW264.7 macrophage cell line based on the MAPK signaling pathway. Furthermore, DNFB modifies proteins in mouse macrophages and skin tissue of NC/Nga mice, resulting in MIP-2 gene expression. Additionally, DNFB-induced ROS generation mediates MIP-2 gene expression in macrophages (20, 21) . In the present study, we investigated the expression patterns of MHC class II and costimulatory molecules such as CD80, CD83, and CD86 in a DNFB-treated macrophage cell line, RAW 264.7 cells (Fig. 2) . DNFB treatment induced expression of MHC class II molecules and CD80 in a time-dependent manner. In contrast to the effect of DNFB on DCs (9, 11, 13) , our results showed that CD86 expression was unchanged in DNFB-treated macrophage cells. Furthermore, we observed that CD83 expression was induced in DNFB-treated RAW 264.7 cells at 3 h, and that the levels subsequently declined over the remaining time points. To determine whether DNFB induced expression of MHC class II and costimulatory molecules in primary immune cells in vitro, we analyzed the effects of DNFB on the expression of cell surface markers in splenocytes, peritoneal cavity cells, and cells of the mesenteric lymph node from BALB/c and NC/Nga mice. The expression of MHC class II molecules and CD80 increased in the CD45R/B220 + cells of splenocytes (Fig. 3) . Furthermore, CD83 expression increased transiently and then decreased in the CD45R/B220 + cell population of splenocytes and mesenteric lymph node cells (Fig. 4) , which was consistent with the results for the RAW 264.7 macrophage cell line (Fig. 2) . However, CD83 expression was not induced in peritoneal cells. In summary, our observations demonstrate that the skin sensitizer DNFB increased expression of MHC class II molecules and CD80 in the macrophage cell line and primary immune cells in vitro, as observed in DCs. CD83 expression declined after DNFB treatment in vitro. Furthermore, induction of CD80 and MHC class II molecule expression and the decrease in CD83 expression by DNFB treatment in vitro were validated in splenocytes of BALB/c and NC/Nga mice. However, CD83 expression following DNFB treatment in vitro was not examined in the peritoneal CD11b + cells from BALB/c and NC/Nga mice. Therefore, in vivo experiments and studies on differential immune cell populations such as CD11b + cells in the peritoneal cavity will be helpful to attain a better understanding of AD pathogenesis.
MATERIALS AND METHODS
Reagents
DNFB was purchased from Sigma (St. Louis, MO, USA). FITC-conjugated anti-MHC class II antibodies, FITC-conjugated anti-CD11b antibodies, APC-conjugated anti-CD11b antibodies, FITC-conjugated anti-CD80 antibodies, PE-conjugated anti-CD83 antibodies, APC-conjugated anti-mouse CD86 antibodies, FITCconjugated anti-CD45R/B220 antibodies, and Pacific Blue-conjugated anti-CD45R/B220 antibodies were purchased from BD Biosciences (San Diego, CA, USA).
Cell culture and DNFB treatment
We obtained the RAW 264.7 mouse macrophage cell line from the American Type Culture Collection (Manassas, VA, USA). The cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 100 U/ml penicillin, and 100 μg/ml streptomycin at 37 o C under a humidified atmosphere of 95% air and 5% CO2. Cell cultures were maintained until passage 20 and then discarded. Cells were treated with DNFB (5 μg/ml) at 37 o C with 5% CO2 for the indicated time periods.
Microarray analysis
Total RNAs from RAW 264.7 cells and DNFB-treated RAW 264.7 cells were isolated using Trizol (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. RNA quality was controlled using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). All microarray experiments were performed with twin array cDNA chips from E-Biogen Inc. (Seoul, Republic of Korea). Target cRNA probes were synthesized and hybridization were performed using an Agilent Low RNA Input Linear Amplification kit (Agilent Technologies) according to the manufacturer's instructions. Briefly, 1 μg of total RNA was reverse transcribed using the T7 promoter primer mix and MMLV-RT. Amplified and labeled cRNA was purified on the cRNA Cleanup Module (Agilent Technologies). The labeled cRNA target was quantified using a ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA). After checking labeling efficiency, cRNA was fragmented and resuspended with 2× hybridization buffer and pipetted directly onto an assembled Agilent Mouse Oligo Microarray (44K). The arrays were hybridized at 65°C for 17 h using a hybridization oven (Agilent Technologies). The hybridized microarrays were washed according to the manufacturer's protocol.
Data acquisition and analysis
Hybridized images were scanned using an Agilent DNA microarray scanner and quantified with Feature Extraction Software (Agilent Technologies). All data were normalized, and foldchanged genes were selected using GeneSpringGX 7.3 (Agilent Technologies). Gene classification was based on searches done in the BioCarta (http://www.biocarta.com/), GenMAPP (http:// www.genmapp.org/), DAVID (http://david.abcc.ncifcrf.gov/), and Medline databases (http://www.ncbi.nlm.nih.gov/).
Reverse transcription-polymerase chain reaction (RT-PCR) analysis
To analyze CD83 expression, total RNAs were extracted with an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) from RAW 264.7 cells or skin tissues, and cDNA was generated as described previously (19) . One microliter of the cDNA mixture was subjected to the standard PCR reaction for 25 cycles of denaturation for 30 sec at 95ºC, annealing for 60 sec at 58ºC , and elongation for 60 sec at 72 o C. The primer sequences used are as followings. Mouse CD83, 5'-CGGAGAGCAAGCAAAACAGC-3' (sense), and 5'-TGTAGCTTCCTTGGGGCATC-3' (anti-sense). Mouse GAPDH, 5'-ATGGTGAAGGTCGGTGTGAACG-3' (sense), and 5'-GTTGTC ATGGATGATCTTGGCC-3' (anti-sense). PCR products were visualized with ultraviolet light after being resolved on a 1% agarose gel.
Isolation of spleen and lymph node cells
We used BALB/c and NC/Nga mice. Seven-week-old male specific-pathogen-free mice were obtained from Central Lab. Animal Inc. (Seoul, Republic of Korea). All animal procedures were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Veterinary Research and Quarantine Service of the Republic of Korea. This protocol was approved by the Institutional Animal Care and Use Committee of Hallym University (permit number: Hallym 2010-83). Mice were sacrificed under Zoletil 50 and Rompun anesthesia. To determine the expression of MHC class II and costimulatory molecules in the splenocytes and cells of the mesenteric lymph node, tissues were removed aseptically, immediately minced in RPMI 1640 culture medium, and passed through a mesh to obtain single cell suspensions. The peritoneal cells were collected from a mouse body with 10 ml RPMI 1640 culture medium. After the cells were washed twice with PBS, erythrocytes were removed by treating them with 5 ml of a red blood cell lysis buffer containing 20 mM Tris-HCl (pH 7.2) and 140 mM ammonium chloride at 37 o C for 5 min, as described previously (26) . The cells were counted with the aid of trypan blue dye exclusion. 
